News

AFFiRiS announces Phase 2 study in Parkinson’s and new focus on neurodegenerative diseases

Valneva Expands its Commercial Operations with the Opening of its French Commercial Office

QuantSeq-UMI Pipeline is Now Available on Partek® Flow®

Im Takt: Neue Therapie bei Herzinsuffizienz im Forschungsvisier

Valneva Announces End of Phase 2 Meeting with the FDA for its Chikungunya Vaccine Candidate

KidsAP: Smartes Blutzuckermanagement für Kleinkinder

HOOKIPA’s Gilead Sciences Collaboration for HIV and HBV Therapeutic Vaccines Advancing Towards Clinical Entry

Alzheimer's: New ultrasound technique significantly improves brain performance

HOOKIPA Announces First Patient Dosed in Phase 1/2 Clinical Trial for HB-201 for the Treatment of Human Papillomavirus 16-Positive Cancers

MPN: Bösartige Erkrankungen des Blutsystems im Fokus

Uni Wien: Mit Genen Krebszellen zum Leuchten bringen

WWTF fördert Forschungsprojekte der MedUni Wien im aktuellen Life Science Call Imaging

Valneva Completes Delisting from the Vienna Stock Exchange

Phenaris: 3rd place at i2b Business Plan Competition

Dekadenrückblick am IMBA

TU Wien: Zwei Preise für das ICC Water & Health

IMBA: A decade in review

WWTF: Funding decision Life Sciences 2019 Multimodal Imaging

AstraZeneca: Gemeinsam stark für die Erwachsenen von morgen

MedUni Vienna: Personalised medicine offers new hope to cancer patients